

Shubham Pant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2050960/publications.pdf>

Version: 2024-02-01

30
papers

848
citations

567281

15
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

1373
citing authors

#	ARTICLE	IF	CITATIONS
1	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer, 2022, 22, 14.	2.6	5
2	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
3	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	9.4	22
4	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Annals of Surgery, 2021, 273, 806-813.	4.2	61
5	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Journal of Gastrointestinal Oncology, 2021, 12, 2268-2274.	1.4	0
6	Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.. Journal of Clinical Oncology, 2021, 39, 299-299.	1.6	40
7	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2021, 39, 1089-1098.	2.6	19
8	Comprehensive Clinical and Molecular Characterization of KRAS ^{G12C} -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	3.0	31
9	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	3.7	42
10	Pancreas Cancer-Associated Pain Management. Oncologist, 2021, 26, e971-e982.	3.7	29
11	Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e153-e165.	3.8	12
12	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	2.8	35
13	Regarding HER2-Amplified Biliary Tract Cancer. Oncologist, 2021, 26, e1664.	3.7	0
14	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 259-272.	1.6	3
15	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 271, 996-1002.	4.2	34
16	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	4.3	105
17	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 5406-5415.	2.8	9
18	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 93-106.	1.6	7
20	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	3.3	21
21	Barriers to Pancreatic Cancer Clinical Trials Enrollment. <i>Oncology</i> , 2020, 34, .	0.5	1
22	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.	4.3	13
23	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	7.0	71
24	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 78-91.	4.4	19
25	Combination Drug Development in BRAF Mutant Colorectal Cancer. <i>Oncoscience</i> , 2018, 5, 51-53.	2.2	1
26	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 614-618.	1.3	14
27	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , 2016, 24, 1150-1158.	8.2	114
28	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	2.8	76
29	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014, 120, 1780-1786.	4.1	23
30	Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.. <i>Blood</i> , 2008, 112, 2172-2172.	1.4	0